Frontlight ResearchEarly access
CompletedPhase 2
Phase 2 Study of pH Gastrilex™ (Enteric-Coated Amorphous Calcium Carbonate Capsules) in Moderate-to-Severe Crohn's Disease
Key facts
- Who runs it
- Soroka University Medical Center
- Where
- Israel1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 23 people enrolled
- Started
- 11 Jun 2023
- Ended
- 19 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PH Gastrilex
- Placebo Comparator
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Signed informed consent form
- Men and women, age 18 years and older
- Moderate to severe CD patients. Moderately active disease will be defined by a CDAI score between 220 to 450, and severe disease for CDAI score greater than 450
Who cannot take part
- Participation in a clinical trial with, or use of, any investigational agent within 30 days or 5 half-lives, whichever is longer, before starting treatment in the trial
- Subject who is taking oral corticosteroids:; Budesonide >9mg/day; Prednisone or equivalent> 20 mg/day; Or has not been on a current course for>14 days prior to colonoscopy
- Subjects who received an approved biological agent less than 16 weeks prior screening
- Subjects whose treatment dose has not been stable for at least 14 days before Baseline, or who discontinued treatment within 14 days before Baseline
- Other significant medical conditions that may require intervention during the trial
- Women patients who are pregnant or breastfeeding. Women patients must have a negative urine or serum test at screening and a negative urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of human chorionic gonadotropin [hCG] at baseline, within 24 hours prior to the start of any investigational agent). Male patients with female sexual partners who are pregnant
- Hypoparathyroidism
- Subjects with consistent hypercalcemia or hypercalciuria
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This Phase 2 study aims to evaluate the safety, tolerability, and efficacy of pH Gastrilex™, an enteric-coated capsule formulation containing amorphous calcium carbonate (ACC), in adults with moderate-to-severe Crohn's disease.
The 2 groups in the trial
- PH Gastrilex™Treatment being tested
PH Gastrilex™ (Amorphous Calcium Carbonate)
- Placebo groupPlacebo, for comparison
Placebo Followed by PH Gastrilex™ (Amorphous Calcium Carbonate)
Treatment: Placebo Comparator
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective, Randomized, Parallel, Double Blind, Placebo-Controlled Study, Followed by an Open Label Extension, to Assess the Safety, Tolerability, and Efficacy of pH Gastrilex™ (Enteric-Coated Capsules Containing Amorphous Calcium Carbonate) Administered Concomitantly With Best Available Treatment (BAT) in the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
- Record updated
- 10 November 2026